Search - tctmd.com

Displaying 741 - 760 of 1042

Sort: Relevancy | Date

News Conference News EAS 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Yael L. Maxwell

April 26, 2017

News Daily News

Oktoberfest Revelers Show That Drinking Alcohol Gets the Heart Racing

Todd Neale

April 26, 2017

News Daily News

Choline, Common in Eggs and Liver, Raises TMAO Levels and Increases Platelet Aggregation

Michael O'Riordan

April 24, 2017

News Daily News

Who Should Get a Statin? Guidelines Don’t Match Up

Michael O'Riordan

April 20, 2017

News

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

Michael O'Riordan

April 13, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Conference News ACC 2017

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

Michael O'Riordan

March 21, 2017

Presentation ACC 2017

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Presenter: Jeff Weitz

March 20, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

Yael L. Maxwell

March 18, 2017

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

L.A. McKeown

March 18, 2017

News Conference News ACC 2017

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Michael O'Riordan

March 15, 2017

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Conference News ACC 2017

Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions

Shelley Wood

March 09, 2017

News Conference News ACC 2017

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

L.A. McKeown

March 09, 2017

Advertisement

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Oktoberfest Revelers Show That Drinking Alcohol Gets the Heart Racing

Choline, Common in Eggs and Liver, Raises TMAO Levels and Increases Platelet Aggregation

Who Should Get a Statin? Guidelines Don’t Match Up

Mortality and CVD Decline in Patients With Diabetes, but Biggest Strides Seen for Nonfatal Outcomes

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI

EINSTEIN CHOICE: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Fish Oils: Yes for HF and Secondary Prevention, No for the General Population, Says AHA

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Does Hormone Replacement Therapy Curb Atherosclerosis? New Imaging Study Opens Old Questions

Erectile Dysfunction Meds Linked to Fewer Death and HF Hospitalizations After MI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content